ESMO 2022 Conference Coverage
Playback speed
10 seconds
ESMO 2022 on the Phase 3 HIMALAYA Study: Impact of Viral Aetiology of Tremelimumab + Durvalumab in Unresectable HCC
By
ESMO 2022 Conference Coverage
FEATURING
Stephen L. Chan
By
ESMO 2022 Conference Coverage
FEATURING
Stephen L. Chan
79 views
September 30, 2022
Comments 0
Login to view comments.
Click here to Login
GI